News coverage about Apricus Biosciences (NASDAQ:APRI) has trended positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apricus Biosciences earned a news impact score of 0.28 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.4488633415426 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Several equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Apricus Biosciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. HC Wainwright cut shares of Apricus Biosciences from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research report on Friday, February 16th. Finally, ValuEngine raised shares of Apricus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
Apricus Biosciences (NASDAQ:APRI) traded down $0.03 on Friday, hitting $0.85. 354,705 shares of the company traded hands, compared to its average volume of 1,970,000. Apricus Biosciences has a twelve month low of $0.63 and a twelve month high of $3.34. The firm has a market capitalization of $12.46, a PE ratio of -0.79 and a beta of 0.96.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.